Ozgen, A. G.Karadeniz, M.Erdogan, M.Berdeli, A.Saygili, F.Yilmaz, C.2019-10-272019-10-2720091720-8386https://doi.org/10.3275/6184https://hdl.handle.net/11454/43130Introduction: Interleukins and cytokines play an important role in the pathogenesis of many cancers. We aimed to evaluate the interleukin (IL)-6 gene polymorphisms in patients with papillary thyroid carcinoma (PTC) and control subjects. Material and methods: In this study, 42 patients with PTC and 340 healthy controls were included. Peripheral blood samples were taken from control group and patients, and blood samples were preserved at -80 C in tubes containing Na-EDTA. Results: We also found a statistically significant difference between patients with PTC and the control group with respect to IL-6 genotype (p<0.05). IL-6 gene polymorphism in patients with PTC patients did not reveal statistically significant difference between the 2 groups (size of tumor >1 cm and <1 cm), multicentricity, RET-PTC types and capsule invasion (p>0.05). We also did not find a statistically significant difference between patients with PTC and the control group with respect to IL-6-gene allele frequency (p>0.05). Discussion: Our data suggest that the IL-6 G-174 C polymorphism could play a role in thyroid cancer risk, but there is no effective role as a prognostic factor. (J. Endocrinol. Invest. 32: 491-494, 2009) (C) 2009, Editrice Kurtisen10.3275/6184info:eu-repo/semantics/closedAccess(-174) G/C polymorphismininterleukin-6 genepapillary thyroid carcinomaArticle326491494WOS:00027159480000219494710Q4